Enteroendocrine L-cell derived peptide hormones, notably glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2), have become important targets in the treatment of type 2 diabetes, obesity and intestinal diseases. As gut microbial imbalances and maladaptive host responses have been implicated in the pathology of obesity and diabetes, this study aimed to determine the effects of pharmacologically stimulated GLP-1 and GLP-2 receptor function on the gut microbiome composition in diet-induced obese (DIO) mice. DIO mice received treatment with a selective GLP-1 receptor agonist (liraglutide, 0.2 mg/kg, BID) or dual GLP-1/GLP-2 receptor agonist (GUB09-145, 0.04 mg/kg, BID) for 4 weeks. Both compounds suppressed caloric intake, promoted a marked weight loss, improved glucose tolerance and reduced plasma cholesterol levels. 16S rDNA sequencing and deep-sequencing shotgun metagenomics was applied for comprehensive within-subject profiling of changes in gut microbiome signatures. Compared to baseline, DIO mice assumed phylogenetically similar gut bacterial compositional changes following liraglutide and GUB09-145 treatment, characterized by discrete shifts in low-abundant species and related bacterial metabolic pathways. The microbiome alterations may potentially associate to the converging biological actions of GLP-1 and GLP-2 receptor signaling on caloric intake, glucose metabolism and lipid handling.
25 × (98 °C for 10 s, 55 °C for 20 s, 72 °C for 20 s), 72 °C for 5 min) with the forward primer S-D-Bact-0341-b-S-17 (5′-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCW-GCAG-3′) and reverse primer S-D-Bact-0785-a-A-21 (5′-GTCTCGTGGGCTCGG-AGATGTGTATAAGAGACAGG ACTACHVGGGTATCTAATCC-3′) with Illumina adapters attached. Indexes were added in a subsequent PCR (98 °C for 30 sec, 8 × (98 °C for 10 s, 55 °C for 20 s, 72 °C for 20 s), 72 °C for 5 min) using the Illumina Nextera Index Kit V2 and the attachments were verified by running the products on an agarose gel. Products from the nested PCR were pooled and the resulting library purified with magnetic beads. The DNA concentration of the pooled libraries was measured fluorometrically. The final 16S rDNA amplicon libraries were sequenced on an Illumina MiSeq using the MiSeq Reagent Kit V3 (Illumina) for 2× 300 bp paired-end sequencing.
Microbiome diversity and richness analysis. The 16S rDNA amplicons were analysed on rarefied data with 13,730 reads per sample. A 64-bit version of USEARCH and mothur were used in combination with bioinformatic tools developed and reported previously 43, 44 . After tag identification and trimming, all sequences from all samples were pooled and paired-end reads merged. Ambiguous and error prone sequences were discarded, and remaining sequences were clustered into operational taxonomic units (OTUs) with 97% sequence similarity using USEARCH 43 . Chimeric OTUs were discarded based on comparison with the Ribosomal Database Project classifier training set v9 using UCHIME 45, 46 . Taxonomic assignment of the OTUs was done using the database from the Ribosomal Database Project 47 . Species richness, Shannon diversity index and Bray-Curtis dissimilarities were computed and principal coordinate analyses (PCoA) were conducted with R 48, 49 . Differences in species richness and Shannon diversity between paired samples at the two timepoints were assessed using a two-sided Wilcoxon signed-rank test. Compositional differences between study groups were measured using Bray-Curtis dissimilarity, which was calculated based on the OTU abundances and projected on the first two dimensions of a PCoA plot 49 . Both sample timepoints were included in the distance matrices, though the resulting PCoA plots were split into two time points for illustrative purposes. Comparing compositional similarity was evaluated using PERMANOVA test (Permutational Multivariate Analysis of Variance, Adonis test from the R-package Vegan) and Bray-Curtis dissimilarity. All p-values were corrected for multiple testing using Benjamini Hochberg False Discovery Rate (FDR) and were considered statistically significant when p < 0.05.
Whole-Genome Shotgun sequencing and data analysis.
A subset of the paired samples was further evaluated by whole-genome shotgun sequencing (chow, n = 7; DIO-vehicle, n = 5; DIO-liraglutide, n = 10; DIO-GUB09-145, n = 11). Genomic DNA was randomly cut into fragments of approximately 350 bp by restriction enzyme. NEBNext UltraTM Library Prep Kit for Illumina (New England Biolabs, Ipswich, MA) was used for library construction. The prepared DNA libraries were evaluated using Qubit 2.0 fluorometer quantitation and Agilent 2100 Bioanalyzer for assessment of fragment size distribution. Quantitative real-time PCR was used to detect the concentration of the final library before sequencing. Whole-genome sequencing (WGS) was performed using 2× 150 bp paired-end sequencing on an Illumina HiSeq platform. WGS output was quality trimmed using Trimmomatic removing the first 10 bp and cutting reads at 3′-end with a sliding window of 4 bp and minimum mean phred score at 15 to generate high-quality reads 50 . Reads shorter than 60 bp or mapping to the mouse reference genome were discarded using Bowtie2 51 . De novo assembly was performed for each sample using Megahit and contigs at least 500 bp long were used for gene prediction using Prodigal 52, 53 . Gene predictions from all samples were combined and metagenomic species (MGS) were created based on a mice gene catalog and by binning genes that were highly co-abundant across samples 37, 54 . Taxonomical annotation was performed using BLASTn against reference sequences in the NCBI RefSeq database (version from 120417) 55 . Genes were annotated to species level using 95% identity and 80% coverage; to genus, family, order and class level using 80% identity and 80% coverage, and to phylum level using 65% identity and 50% coverage. Furthermore, a species was assigned a taxonomy to a given level if more than a given percentage of genes were consistently annotated to a specific taxon. For species, this was 80%, for genus 75%, family and order 60%, class 50%, and for phylum 40% of the genes that were consistently annotated to the respective taxonomical level. An MGS counts table was created based on the total gene counts for each MGS. The MGS counts table was downsampled (rarefied) and normalized according to effective gene length (accounting for read length) and then normalized to sum to 100%, resulting in relative abundance estimates of each MGS.
Metagenomic species clustering and statistics.
For species present in 10% or more samples (n = 609) a linear mixed model (LMM) regression was performed to test for abundance changed within each DIO mouse treatment group using the lme4 package in the R environment 56 . Relative abundances were log10-transformed and regressed against the interaction between treatment and sampling time (baseline, termination) and the individual mouse was modelled as a random effect. A post-hoc Tukey test was used to determine which groups differed significantly. For graphical clarity, abundance profiles of changing species were clustered using Partitioning Around Medoids (PAM) 57 (k = 4, was chosen manually). Correlations between significant differential abundant species and metabolic measures (% body weight loss, total food intake, triglycerides, cholesterol, fasting glucose and AUC glucose) were calculated using a correlation test (Spearman) and corrected for multiple testing (Benjamini Hochberg). Functional analysis. Functional annotation was obtained by mapping genes to the eggNOG orthologous database using the Emapper software 58 in HMMER mode (e-value < 0.001). Functional annotation to the KEGG database was performed using MOCAT2 59, 60 . Only, KEGG modules found in >10% of the samples were used for statistical analysis. Abundance statistics for functional annotation was done as described for species abundances.
Results
Liraglutide and GUB09-145 improve metabolic parameters in DIO mice. Following 35 weeks of feeding, DIO mice showed significantly increased body weight (53.0 ± 0.6 g, n = 45) compared to chow controls (32.1 ± 0.2 g, n = 10, p < 0.001, Fig. 1A,B ). Daily food intake curves are indicated in Fig. 1C . Cumulated energy intake was significantly higher in vehicle-dosed DIO mice (n = 15) compared to chow-fed controls ( Fig. 1D , p < 0.001). In addition, vehicle-dosed DIO mice showed mildly impaired oral glucose tolerance at treatment day 27 compared to vehicle-dosed chow controls ( Fig. 1E ,F). Compared to chow controls, vehicle-dosed DIO mice also displayed significantly increased fasting glucose measured on day 14 (p < 0.001, Fig. 1G ) and terminal insulin levels (p < 0.01, Fig. 1H ), lowered plasma TG (p < 0.05, Fig. 1I ), and elevated TC (p < 0.001, Fig. 1J ). A significant weight loss was observed in DIO mice during four weeks of treatment with liraglutide (0.2 mg/kg, SC, BID, n = 15) and GUB09-145 (0.04 mg/kg, SC, BID, n = 15) (p < 0.01, Fig. 1B ). Compared to baseline (treatment day 0), terminal weight loss amounted to 27.3 ± 1.1% (14.4 ± 0.7 g) and 17.3 ± 1.2% (9.3 ± 0.6 g) in liraglutide and GUB09-145 treated DIO mice, respectively ( Fig. 1A,B ). Both compounds significantly reduced high-fat diet intake within the first days of dosing whereafter food intake was gradually normalized (Fig. 1C ). Liraglutide and GUB09-145 improved glucose tolerance, with GUB09-145 being slightly more effective (Fig. 1E,F ). Compared to vehicle controls, both compounds also improved fasting blood glucose levels (p < 0.001, Fig. 1G ) and hypercholesterolemia (p < 0.001, Fig. 1J ). Only liraglutide improved hyperinsulinemia in the DIO mice (p < 0.01, Fig. 1H ). Compared to chow-fed mice, plasma triglyceride levels were slightly reduced in DIO mice (p < 0.05) and were unaffected by drug treatment (Fig. 1I ).
Gut microbiome structural changes determined by 16S rDNA amplicon sequencing. Baseline
and terminal gut bacterial signatures were homogenous within each individual group ( Fig. 2A,B ). The PCoA plots demonstrated substantial compositional differences (beta-diversity) between chow-fed and DIO mice (r 2 = 0.49, p = 0.001) which were largely unaffected by vehicle dosing (chow/DIO: r 2 = 0.06/0.04, p = 0.21/0.25; Fig. 2A,B ). In contrast, drug treatment promoted relatively discrete changes in the microbiome signature in DIO mice (liraglutide/GUB09-145: r 2 = 0.14/0.15, p = 0.001/0.001). In addition, microbial alpha-diversity analyses were performed based on 16S sequencing data. Compared to chow-fed controls, DIO mouse controls showed significantly reduced gut bacterial richness (number of observed OTUs, baseline p < 0.001; termination p = 0.001, Fig. 2C ) and Shannon diversity index (which accounts for both species richness and evenness in abundance, baseline p = 0.02; termination p = 0.72, Fig. 2D ).
At baseline, all DIO groups showed similar lowered level of bacterial richness and diversity. Dominant phyla in chow-fed controls were Bacteroidetes, Firmicutes, Proteobacteria, and Actinobacteria (Fig. 3A) . The reduction in bacterial diversity in DIO mice was mainly attributed to enrichment of Firmicutes and Proteobacteria with a parallel reduction in the abundancy of Bacteroides (Fig. 3B ). At the bacterial family level, the gut microbiome changes in DIO mice were associated with significantly increased relative abundance of members of the Firmicutes phylum (Peptostreptococcaceae, p < 0.001), Proteobacteria (Proteobacteria_unclassified, p = 0.013), and significant abundance reductions of members belonging to the Bacteroidetes phylum driven by a substantial loss of Porphyromonadaceae (p < 0.001) and Prevotellaceae (p < 0.001) ( Fig. 3B ).
Compared to baseline, liraglutide and GUB09-145 treatment promoted largely similar directional shifts in DIO mouse gut microbiome signatures. Nevertheless, the microbiome signatures remained highly different from the corresponding profile in chow-fed controls ( Fig. 2A,B ). Gut microbial (OTU) richness was significantly increased following GUB09-145 treatment (p = 0.03) and tended to be higher after liraglutide treatment although this effect did not attain statistical significance (Fig. 2C ). In contrast, vehicle-dosed DIO mice remained at lower gut microbial richness (p = 0.68, Fig. 2C ). Shannon diversity changed only in compound-treated DIO mice (vehicle, p = 0.11; liraglutide, p = 0.02; GUB09-145, p = 0.009, Fig. 2D ). In all DIO mice, gut microbiome signatures were unchanged at the family level (p adj > 0.05) following treatment with vehicle, liraglutide or GUB09-145 as compared to baseline ( Fig. 3B ).
Gut microbiome structural changes determined by deep sequencing shotgun metagenomics.
Consistent with the finding of reduced bacterial richness and diversity in DIO mice, gene richness was lower in all DIO mouse groups (average 530,000-560,000 genes) compared to chow-fed mice (average 630,000 genes). The shotgun analysis yielded highly similar overall differences in microbiome signatures in the study groups as also identified by 16S sequencing (Figs 2A,B and 4A,B) , further supporting the observation that liraglutide and GUB09-145 treatment resulted in larger microbiome compositional changes compared to vehicle-dosed DIO mice. Baseline gene richness measured at the species level was significantly lower in DIO mice compared to chow-fed controls (p < 0.001) and remained lower following vehicle dosing (p < 0.001, Fig. 4C ). In contrast, Shannon diversity was similar in chow-fed and DIO mice ( Fig. 4D ). Compared to baseline, gene richness and diversity did not differ significantly in liraglutide and GUB09-145 treated DIO mice ( Fig. 4C,D) .
A total of 37 species significantly changed abundance in response to either liraglutide or GUB09-145 treatment (LMM, Treatment:Time, p < 0.05; post-hoc Tukey test, p < 0.05). The 37 species were grouped into four distinct clusters ( Fig. 5 , right panel). Cluster 1 comprised species with reduced abundance after liraglutide or GUB09-145 treatment; Cluster 2 comprised species with increased abundance primarily after liraglutide treatment; Cluster 3) comprised species with reduced abundance primarily after liraglutide treatment; and Cluster 4) comprised species with increased abundance after both liraglutide and GUB09-145 treatment. To assess the relationship between these regulated species and corresponding changes in the metabolic phenotype, within-subject change in the relative abundance of each individual species was correlated to six metabolic parameters assessed in the study (Fig. 5 , left panel). Cluster 1 (15 species) was dominated by Lachnospiraceae and Clostridiales species and correlated to improvements in TC and glucose tolerance. Cluster 2 (5 species) comprised Clostridiales spp., Burkholderiales bacterium YL45, Oscillospiraceae sp. and Akkermansia muciniphila, which correlated to reduced body weight and caloric intake following liraglutide and GUB09-145 treatment. Cluster 3 (12 species) comprised Clostridia and Clostridiales spp., Oscillospiraceae sp., Figure 6 depicts abundance-shifted KEGG modules and associated functional pathways. Most conspicuously regulated pathways included Lipid metabolism, Protein processing, Sulfur metabolism, and Two-component regulatory system (phosphokinase-associated signal transduction). Whereas DIO control mice showed most consistent changes in KEGG modules associated with reduced bacterial sulfur metabolism, liraglutide and GUB09-145 effects on the gut microbiome were largely associated to effects on bacterial lipid metabolism (increased by liraglutide), sulfur metabolism (increased by both compounds), and Two-component regulatory system (modulated by both compounds).
Discussion
Host-gut microbiota interaction is suggested to play a contributory role in the therapeutic effects of antidiabetics and weight loss promoting drugs. Among the various mechanisms proposed, the gut microbiota has been reported to modulate the expression and secretion of glucagon-like peptide hormones from enteroendocrine cells 27, 61 . As GLP-1 and GLP-2 have become important targets in the treatment of type 2 diabetes, obesity and malabsorptive conditions 16, 17, 62 , we therefore characterized gut microbiome signatures in DIO mice treated with liraglutide, a selective GLP-1 receptor agonist, or GUB09-145, a potent dual GLP-1/GLP-2 agonist 26 .
16S rDNA amplicon sequence analysis and deep-sequenced shotgun metagenomics were applied for comprehensive mapping of gut microbiome changes caused by pharmacological intervention in DIO mice. Notably, gut microbiome signatures were highly homogenous within all individual experimental groups, which may be ascribed to the application of paired fecal samples to reduce interindividual variability in combination with a stable phenotype. This permitted detection of discrete, however consistent, alterations in the gut microbiome composition in DIO mice during the course of treatment. Compared to chow feeding, high-fat feeding for 35 weeks resulted in substantial rearrangement of the gut microbiota reflected by reduced bacterial community richness and diversity accompanied by highly consistent changes in the abundance of major bacterial divisions, dominated by phylum-level taxonomic shifts in Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria. This general gut microbial profile, including a higher Firmicutes:Bacteroidetes ratio, is in agreement with previous reports in high-fat diet fed mice 9,63,64 and obese humans 5, 6, 65, 66 . Notably, this characteristic microbial profile is reversible by dietary intervention 7, 65, 67 . Firmicutes are major producers of short-chain fatty acids (SCFAs), including butyrate, and this phylum has been proposed to play a contributory role in host adiposity by facilitating more efficient nutrient processing and energy extraction 6, 9 . However, it should be noted that the biological relevance of the Firmicutes/Bacteroidetes ratio in predicting obesity has been disputed 8, 68 . Also, as obesity-resistant mice assume an increased Firmicutes:Bacteroidetes ratio when fed a high-fat diet 63 , this emphasizes the importance of the diet as a major factor for gut bacterial community-wide changes in obesity.
Compared to the extensive gut microbiome alterations promoted by high-fat feeding per se, long-term liraglutide and GUB09-145 treatment led to relatively minor shifts in bacterial communities in DIO mice. Bacterial diversity measured at the species level did not change significantly following liraglutide and GUB09-145 treatment, which indicates that drug treatment effects on gut microbiome signatures in DIO mice were attributed to re-arrangement of low-abundant species. Liraglutide and GUB09-145 treated DIO mice showed notable commonalities in gut microbiome changes, dominated by reduced abundancy of species within Firmicutes (Lachnospiraceae, Clostridiales) and parallel increases in the abundance of species representing Proteobacteria (e.g. Burkholderiales bacterium YL45) and Verrucomicrobia (e.g. Akkermansia muciniphila) as well as Firmicutes (Clostridiales, Oscillospiraceae) . The complex changes in gut bacterial distribution following liraglutide and GUB09-145 treatment is further underscored by drug treatment effects on bacterial species not regulated in DIO mice per se, including increased abundance of Firmicutes (Clostridium) and Proteobacteria (Desulfovibrionaceae) members.
Liraglutide has recently been reported to induce gut microbial structural changes in DIO mice, dominated by changes in the distribution of Proteobacteria and Verrucomicrobia phylotypes without affecting the abundance of Firmicutes 69 . Our study indicates that the largely unchanged proportion of Firmicutes following liraglutide treatment is explained by bidirectional changes in the abundance of bacterial species within this phylum. The complicated structural changes in the gut microbiome changes following liraglutide and GUB09-145 treatment therefore prompted us to perform correlations between changes in individual metabolic parameters and species abundance. Notably, body weight loss was correlated to increased abundance of Akkermansia muciniphila, a mucin-degrading SCFA-producing species which has been reported decreased in obesity and show negative correlation to markers of gut permeability and inflammation 70 . Although there is limited direct evidence for this species having functional effects on host metabolic profile, studies in DIO mice have demonstrated reduced adiposity and improved glucose tolerance following oral administration of Akkermansia muciniphila 71, 72 . Importantly, both liraglutide and GUB09-145 have been reported to stimulate intestinal growth by increasing intestinal volume and mucosal surface area in mice 20, 26 . It is therefore tempting to speculate if the intestinotrophic effects of GLP-1 and GLP-2 receptor agonists, leading to increased nutrient absorptive area, could stimulate colonization of mucosa-associated microbial communities. This hypothesis could be tested by assessing the growth properties of the relevant species or by doing histology on intestinal samples with probes directed at the differentially abundant species 73 . Another factor to be considered is the anorectic effects of liraglutide and GUB09-145 26, 74 . As GLP-1 and dual GLP-1/2 receptor agonists have potent inhibitory effects on gastric emptying 26, 74 , and correlations to increased abundance of species members of Clostridiales, Burkholderiales, Oscillospiraceae and Akkermansia muciniphila were driven by suppressed food intake in liraglutide and GUB09-145 treated DIO mice, this suggests that altered gastrointestinal nutrient flow could have influenced the abundance of these bacterial communities. Interestingly, the cholesterol-lowering properties of liraglutide and GUB09-145 were consistently correlated to reduced abundance of several members of Firmicutes (Lachnospiraceae and Clostridiales spp.). Intestinal cholesterol and cholesterol-derived primary bile acids can be metabolized by the colonic bacteria. In contrast to bile acid converting bacteria, only a few cholesterol-reducing bacteria have been isolated 75 . Several bacterial fermentation pathways have been proposed to lower cholesterol levels, including bile acid-converting and SCFA-producing enzymes which may reduce the rate of cholesterol reabsorption and increase cholesterol metabolism 76 . Whether these mechanisms are influenced by reduced abundance of Firmicutes must await further studies. It should also be taken into account that DIO mice show changes in the abundance of Lachnospiraceae depending on the dietary fat source 77 , and suppressed high-fat diet intake by liraglutide and GUB09-145 treatment could therefore potentially have impacted the composition of this bacterial family. Compared to changes in species abundance, more discrete effects were observed on associated KEGG modules, which is likely explained by redundancy of functional metabolic features among regulated bacterial species. The effects of liraglutide and GUB09-145 were predominantly associated to increased bacterial lipid handling and sulfur metabolism. Interestingly, the drug effects on the thiosulfate oxidation module were unrelated to the metabolic phenotype, as vehicle-dosed DIO mice did not show any changes in these KEGG domains compared to chow-fed controls. In particular, correlations to sulfur metabolism were driven by increased abundance of Desulfovibrionales sp., an order mostly consisting of sulfate-reducing species. It is therefore possible that enhanced GLP-1/GLP-2 receptor activity facilitates production of substrates for production of gut bacterial hydrogen sulfide, which have anti-inflammatory properties and may enhance intestinal barrier function 78 .
Limitations of the study should be considered. No internal controls (e.g. extraction blanks) were applied to exclude/define potential contaminating microbial DNA originating from the extraction kit and other reagents used for sample DNA processing. As any potential background signal from the DNA extraction kit is expected to be substantially lower than the mock yield from the positive control (bacterial culture) and mouse fecal samples contained considerably higher bacterial DNA amounts compared to the positive control, this argues for the fecal samples almost solely consisting of biological relevant DNA. The study did not address effects of a selective GLP-2 receptor agonist, which makes it presently unresolved to what extent stimulated GLP-2 receptor function may have contributed to the gut microbiome changes following GUB09-145 treatment. Because the study did not include corresponding drug treatment in chow-fed mice, potential high-fat diet-dependent gut microbial compositional effects of liraglutide/GUB09-145 treatment cannot be ruled out. Also, it remains to be investigated whether the marked weight loss subsequent to suppressed caloric intake could be a major factor for shaping the gut microbiome in liraglutide/GUB09-145 treated DIO mice. This is relevant as weight loss following caloric restriction has been reported to influence gut microbiome composition in DIO mice, although the implications are poorly understood 33, 79 . However, it should be emphasized that use of caloric restriction to control for weight-dependent effects in DIO mouse studies may potentially introduce confounding effects on microbiome signatures due to significant compensatory changes in hunger sensation, feeding pattern, resting metabolic rate and gut morphology which may be disproportionately to that attained by appetite suppressants 80, 81 . In conclusion, DIO mice assumed a phylogenetically similar gut microbiota composition following liraglutide and GUB09-145 treatment, suggesting that GLP-2 receptor stimulation played a marginal role in the microbiome modulatory effects of GUB09-145. The highly similar pattern of microbiome alterations following GLP-1 and dual GLP-1/GLP-2 receptor agonist treatment likely associate to the biological actions of the receptors that converge at several levels with respect to regulation of energy homeostasis, gut morphology and intestinal repair 82 . Whether the discrete shifts in gut bacterial species in DIO mice could potentially contribute to the metabolic effects of pharmacologically stimulated GLP-1 and GLP-2 receptor function or, alternatively, reflect gut microbiota adaptive responses secondary to reduced caloric intake must await further studies. 
